TCT: Guess Who’s Back…Back Again?

After being held in various cities over the recent years, TCT is back home where it belongs – back in the Bay, and joyfully, right in our backyard. We couldn’t be more excited about TCT this year. And no, it’s not just because those of us who live in the city are lucky enough to walk to work for a few beautiful September days.

TopShock Symposium Details for Blog Post


It’s because TopShock is also back! What’s TopShock you might ask? It’s our IVL case contest in which we’ve asked our customers to submit their most challenging IVL cases in a few unique applications, including facilitating Impella access, preserving transfemoral TAVR access and treating critical limb ischemia. Over the last few weeks, a panel of expert judges have been culling through the submitted cases and we’re happy to feature a stellar group of finalists (see image), coupled with our DISRUPT CAD III principal investigators to moderate the session and facilitate the audience voting of who will be awarded the TopShock – we hope you can attend and cast your vote!


And it gets better — TopShock is just the beginning of our presence at TCT. In addition to our training pavilion, we’re co-sponsoring on “Complex lesion management in SFA intervention” on Saturday, September 28th at 8am and 10am (Click Here to Register). 


Also, we’re fortunate to have IVL featured in more than 25 presentations in the meeting’s scientific program. Here are few of the highlights from our perspective, capped off with the first report of our DISRUPT CAD II study on Friday afternoon:


Wednesday, 25 September 2019


PCI in Patients with Heavily Calcified Lesions

Room 207; 12:30 PM - 1:30 PM

    • 1:00pm TCT 27: Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II study (Ziad Ali)
  • 1:15pm TCT 28: Comparative Study of Resource Utilisation Costs and Procedural Times of Percutaneous Coronary Intervention with Rotational Atherectomy vs Intravascular Lithotripsy (Shafeer G. Rashid)

TCT Endovascular: Calcium, Debulking, and Vessel Preparation
Room 156/158; 2:44 PM - 4:50 PM

  • 3:14pm Intravascular Lithotripsy for Calcium: When Does It Work With Case Examples (Peter A. Soukas)


Thursday, 26 September 2019


Poster Abstracts I - Coronary: CHIP

Hall D, Exhibition Level, Moscone South; 9:15 AM - 10:45 AM

  • 9:15am TCT 862: Adjunctive Coronary Calcium Modification: The Bournemouth Experience of Shockwave Intravascular Lithotripsy (Peter O'Kane)


Friday, 27 September 2019


Rotational and Orbital Atherectomy, Cutting/Scoring Balloons, and Lithotripsy

Moderated Posters 7, Exhibit Hall, Exhibition Level, Moscone South; 11:30 AM - 12:30 PM

  • 11:50am TCT 653: Intravascular Lithotripsy for lesion preparation in calcified coronary lesions: First data of prospective observational multicenter registry (Adem Aksoy)
  • 12:00pm TCT 654: Feasibility and safety of Intravascular Lithotripsy in severely calcified left main coronary stenoses (Carlos Salazar)


Innovation & Keynote Theater; 4:00 PM - 5:00 PM         

  • 4:45pm DISRUPT CAD II: A Single Arm Study of Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses (Carlo Di Mario)


Saturday, 28 September 2019


Treatment of Coronary Calcification Coronary: CHIP
Room 151/153; 8:00 AM – 10:00 AM

  • 8:23am Intravascular Lithotripsy for Coronary Calcification: When and How (Jean Fajadet)



What a week! We hope that your schedule permits you to attend a few of the above sessions, or if nothing else, stop by our booth (#1927) for a chat. There’s nothing we love more than engaging with our customers. And for those that aren’t going to the meeting, we’re going to be featuring as much content and data presentations as possible on our Twitter handle – @ShockwaveIVL – so stayed tuned for live updates from SF.


Finally, if you have a few extra minutes of downtime, try to take advantage of some of the best things that San Francisco has to offer – the food, drink, scenery, nightlife – it’s really second to none. If you want any recommendations, we’ll be more than happy to point you in the right direction – just ask!  


See you soon in San Francisco!





Important Safety Information - Coronary


Caution: In the United States, Shockwave C2 Coronary IVL catheters are investigational devices, limited by United States law to investigational use. DISRUPT CAD III Study


Shockwave C2 Coronary IVL catheters are commercially available in certain countries outside the U.S. Please contact your local Shockwave representative for specific country availability. The Shockwave C2 Coronary IVL catheters are indicated for lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic de novo coronary arteries prior to stenting. For the full IFU containing important safety information please visit:


Important Safety Information - Peripheral


Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Indication for Use – The Shockwave Medical Intravascular Lithotripsy (IVL) System is intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.  Not for use in the coronary or cerebral vasculature.


Contraindications – Do not use if unable to pass 0.014 guidewire across the lesion • Not intended for treatment of in-stent restenosis or in coronary, carotid, or cerebrovascular arteries.


Warnings – Only to be used by physicians who are familiar with interventional vascular procedures • Physicians must be trained prior to use of the device • Use the Generator in accordance with recommended settings as stated in the Operator’s Manual


Precautions – Use only the recommended balloon inflation medium • Appropriate anticoagulant therapy should be administered by the physician • Decision regarding use of distal protection should be made based on physician assessment of treatment lesion morphology


Adverse Effects – Possible adverse effects consistent with standard angioplasty include: • Access site complications • Allergy to contrast or blood thinners • Arterial bypass surgery • Bleeding complications • Death • Fracture of guidewire or device • Hypertension/Hypotension • Infection/sepsis • Placement of a stent • Renal failure • Shock/pulmonary edema • Target vessel stenosis or occlusion • Vascular complications. Risks unique to the device and its use: • Allergy to catheter material(s) • Device malfunction or failure • Excess heat at target site


Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions, and adverse events.


true true TCT: Guess Who’s Back…Back Again? Click Here To Read

To keep you apprised of the latest IVL news, education, and cases, please share your selected interests.